Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(FY)Mar 31, 2024 | |
---|---|
Total revenue | 1.48B |
Cost of revenue | 547.93M |
Gross profit | 935.89M |
Operating expense | 533.48M |
Operating profit | 402.41M |
Net non-operating interest income (expenses) | -550K |
Non-operating interest income | --31K |
Non-operating interest expense | --581K |
Net investment income | |
Gain(Loss) on financial instruments designated as cash flow hedges | |
Gain(Loss) on derecognition of available-for-sale financial assets | 186K |
Income from associates and other participating interests | |
Special income (charges) | |
Other non-operating income (expenses) | 2.22M |
Income before tax | 404.27M |
Income tax | 119.14M |
Net income | 285.13M |
Net income continuous operations | --285.13M |
Noncontrolling interests | |
Net income attributable to the company | 285.13M |
Preferred stock dividends | |
Other under preferred stock dividend | 0 |
Net income attributable to common stockholders | 285.13M |
Gross dividend payment | |
Basic earnings per share | 142.5635 |
Diluted earnings per share | 142.5635 |
Dividend per share | |
Currency Unit | JPY |
Accounting Standards | NonUS-GAAP |